ArticleScientific reports2025
Prevalence, clinical reasons and associated factors of extended treatment duration for drug susceptible tuberculosis - a real-world experience.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of risk prediction models for anti-tuberculosis drug-induced liver injury in East Asian populations.Frontiers in public health · 2026Pooled it
- Autoimmune Phenotype Confirmation Intervals and Clinical Indicators in Patients With Latent Autoimmune Diabetes in Adults (LADA) in Southwest China: A Multicenter Retrospective Cross-Sectional Study.Journal of diabetes research · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited research has been conducted on the prevalence and factors associated with extended drug-susceptible tuberculosis (TB) treatment. A retrospective study enrolled drug-susceptible TB patients (January 2018 to December 2020) from a hospital's registry to analyze prevalence, reasons, and factors for extended treatment (≥ 9 months) compared with standard course. Analyzing 221 TB patients, 80 patients received extended treatment. The extended group showed higher hepatitis B infection rates (12.5% vs. 5%, p = 0.043), recent cancer treatment (18.8% vs. 8.5%, p = 0.025), more adverse drug events (ADEs) (grade 3 or more severe ADEs 27.5% vs. 11.3%, p = 0.003), and treatment interruptions (46.3% vs. 18.4%, p < 0.001). Logistic regression highlighted hepatitis B infection (AOR 3.10, p = 0.039), recent cancer treatment (AOR 3.09, p = 0.013), and post-treatment elevated aminotransferase (AOR 2.40, p = 0.014) as independent factors for extended treatment. Extended anti-TB treatment affects 28.7% of patients, with host characteristics and adverse drug effects playing a role in treatment duration. Integrating these factors into treatment strategies is vital for optimal patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.